[
PET imaging
[18F]ML-10
apoptosis
chemotherapy
in vivo
triple negative breast cancer
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
06 Jan 2020
06 Jan 2020
Historique:
received:
04
10
2019
accepted:
12
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
8
1
2020
Statut:
epublish
Résumé
Pathological complete response to the neoadjuvant therapy (NAT) for triple negative breast cancer (TNBC) is predictive of prolonged patient survival. Methods for early evaluation of NAT efficiency are still needed, in order to rapidly adjust the therapeutic strategy in case of initial non-response. One option for this is molecular imaging of apoptosis induced by chemotherapy. Therefore, we investigated the capacity of [ Initially, the induction of apoptosis by different therapies was quantified. We confirmed, in vitro, that paclitaxel or epirubicin, the fundamental cytotoxic drugs for breast cancer, induce apoptosis in TNBC cell lines. Exposure of TNBC models MDA-MB-231 and MDA-MB-468 to these drugs induced a significant increase (p < 0.01) of the apoptotic hallmarks: DNA fragmentation, membrane phospholipid scrambling, and PARP activation. Secondarily, apoptotic fraction was compared to the intracellular accumulation of the radiotracer. [ These results highlighted that PET imaging using [
Identifiants
pubmed: 31907640
doi: 10.1186/s13550-019-0587-5
pii: 10.1186/s13550-019-0587-5
pmc: PMC6944726
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2Subventions
Organisme : Ligue Contre le Cancer
ID : 61200
Références
Breast Cancer Res Treat. 2012 Jan;131(2):357-69
pubmed: 21960111
Clin Med Oncol. 2008;2:319-25
pubmed: 21892293
Radiother Oncol. 2004 Sep;72(3):333-9
pubmed: 15450733
Bioconjug Chem. 2012 Oct 17;23(10):1989-2006
pubmed: 22989049
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Blood Res. 2016 Sep;51(3):157-163
pubmed: 27722125
Exp Oncol. 2012 Oct;34(3):269-76
pubmed: 23070012
Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1400-8
pubmed: 22699524
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16375-80
pubmed: 19805307
Nat Rev Cancer. 2011 Aug 11;11(9):671-7
pubmed: 21833026
Oncol Lett. 2018 May;15(5):6233-6240
pubmed: 29616105
Cell Death Differ. 2004 Sep;11(9):953-61
pubmed: 15195071
Contrast Media Mol Imaging. 2018 Jun 10;2018:9365174
pubmed: 29983648
Mol Imaging Biol. 2019 Jun;21(3):538-548
pubmed: 30218389
Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):47-52
pubmed: 17906858
Proc Natl Acad Sci U S A. 1983 Jan;80(1):160-4
pubmed: 6296863
Anticancer Drugs. 1995 Jun;6(3):443-50
pubmed: 7670143
J Nucl Med. 2010 Aug;51(8):1167-70
pubmed: 20660380
J Nucl Med. 2010 Jun;51(6):837-40
pubmed: 20484422
Clin Cancer Res. 2002 Apr;8(4):971-9
pubmed: 11948102
Cell Res. 2009 May;19(5):625-37
pubmed: 19223854
Bioorg Med Chem. 2014 Jan 1;22(1):341-9
pubmed: 24290974
Bull Cancer. 2013 May;100(5):453-64
pubmed: 23695030
Anticancer Agents Med Chem. 2009 Nov;9(9):1003-11
pubmed: 19663783
Mol Imaging. 2017 Jan 1;16:1536012116685941
pubmed: 28654376
Brain Behav. 2014 Mar;4(2):312-5
pubmed: 24683522
Clin Cancer Res. 2015 Sep 1;21(17):3896-905
pubmed: 25972517
Breast J. 2012 Jul-Aug;18(4):345-50
pubmed: 22607041
Acta Radiol. 2012 Jul;53(6):615-27
pubmed: 22734080
J Nucl Med. 2011 May;52(5):720-5
pubmed: 21498526
J Nucl Med. 2009 May;50(5):774-80
pubmed: 19372481
Br J Cancer. 1996 Jan;73(1):54-60
pubmed: 8554984
PLoS One. 2012;7(6):e38428
pubmed: 22719886